HuGE Literature Finder
Records
1
-
8
| Therapeutic options for mucinous ovarian carcinoma. Gynecologic oncology 2020 Jan . Gorringe Kylie L, Cheasley Dane, Wakefield Matthew J, Ryland Georgina L, Allan Prue E, Alsop Kathryn, Amarasinghe Kaushalya C, Ananda Sumitra, Bowtell David D L, Christie Michael, Chiew Yoke-Eng, Churchman Michael, DeFazio Anna, Fereday Sian, Gilks C Blake, Gourley Charlie, Hadley Alison M, Hendley Joy, Hunter Sally M, Kaufmann Scott H, Kennedy Catherine J, Köbel Martin, Le Page Cecile, Li Jason, Lupat Richard, McNally Orla M, McAlpine Jessica N, Pyman Jan, Rowley Simone M, Salazar Carolina, Saunders Hugo, Semple Timothy, Stephens Andrew N, Thio Niko, Torres Michelle C, Traficante Nadia, Zethoven Magnus, Antill Yoland C, Campbell Ian G, Scott Clare |
| Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. Neoplasia (New York, N.Y.) 2019 May 21 (6): 582-590. Van Nieuwenhuysen Els, Busschaert Pieter, Laenen Annouschka, Moerman Philippe, Han Sileny N, Neven Patrick, Lambrechts Diether, Vergote Igna |
| Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecologic oncology 2019 Feb . Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani N C, Mackay H, Butler M O, Wang L, Siu L L, Kamel-Reid S, Stockley T, Bedard P L, Oza A |
| EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer research 2017 Jun . Etemadmoghadam Dariush, Azar Walid J, Lei Ying, Moujaber Tania, Garsed Dale W, Kennedy Catherine, Fereday Sian, Mitchell Chris, Chiew Yoke-Eng, Hendley Joy, Group Australian Ovarian Cancer Study, Sharma Raghwa, Harnett Paul, Li Jason, Christie Elizabeth L, Patch Ann-Marie, George Joshy, Au-Yeung George, Mir Arnau Gisela, Holloway Timothy P, Semple Timothy, Pearson John V, Waddell Nicola, Grimmond Sean, Köbel Martin, Rizos Helen, Lomakin Ivan, Bowtell David D L, DeFazio An |
| A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecologic oncology 2016 Apr 141 (1): 108-12. Penson R T, Sales E, Sullivan L, Borger D R, Krasner C N, Goodman A K, Del Carmen M G, Growdon W B, Schorge J O, Boruta D M, Castro C M, Dizon D S, Birrer M |
| Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. International journal of oncology 2015 Jun 46 (6): 2389-98. Takenaka Masataka, Saito Motonobu, Iwakawa Reika, Yanaihara Nozomu, Saito Misato, Kato Mamoru, Ichikawa Hitoshi, Shibata Tatsuhiro, Yokota Jun, Okamoto Aikou, Kohno Takas |
| Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Archiv : an international journal of pathology 2014 Aug 465 (2): 193-8. Zannoni Gian Franco, Improta Giuseppina, Chiarello Gaia, Pettinato Angela, Petrillo Marco, Scollo Paolo, Scambia Giovanni, Fraggetta Filip |
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Mar 30 (8): 777-82. Janku Filip, Wheler Jennifer J, Westin Shannon N, Moulder Stacy L, Naing Aung, Tsimberidou Apostolia M, Fu Siqing, Falchook Gerald S, Hong David S, Garrido-Laguna Ignacio, Luthra Rajyalakshmi, Lee J Jack, Lu Karen H, Kurzrock Razel |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: